Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why Did EDX Medical Group Plc LSE:EDX Fall 5.88% in Mixed London Trading?

EDX Medical Group Plc — LSE:EDX fell 5.88% on29 October 2026, with the shares at 8.0p after a decrease of 0.50p on the day.

Ishan Mudgal | 29 October 2026

Why Did Fusion Antibodies Plc LSE:FAB Fall 8.00% in Mixed London Trading?

Fusion Antibodies Plc — LSE:FAB fell 8.00% on29 October 2026, with the shares at 5.75p after a decrease of 0.50p on the day.

Ishan Mudgal | 29 October 2026

Why Did Advanced Medical Solutions Group Plc LSE:AMS Fall 0.18% in Mixed London Trading?

Advanced Medical Solutions Group Plc — LSE:AMS fell 0.18% on29 October 2026, with the shares at 282.5p after a decrease of 0.50p on the day.

Ishan Mudgal | 29 October 2026

Why Did Aptamer Group Plc LSE:APTA Fall 5.00% in Mixed London Trading?

Aptamer Group Plc — LSE:APTA fell 5.00% on29 October 2026, with the shares at 0.285p after a decrease of 0.01p on the day.

Ishan Mudgal | 29 October 2026

Why Did Bioventix Plc LSE:BVXP Fall 2.44% in Mixed London Trading?

Bioventix Plc — LSE:BVXP fell 2.44% on29 October 2026, with the shares at 2,000.0p after a decrease of 50.00p on the day.

Ishan Mudgal | 29 October 2026

Smith & Nephew (LSE:SN.): Why This FTSE 100 Stock Is Drawing Investor Attention on 29 October 2026

• Investors are watching whether operational delivery supports expectations and valuation.

Ankur Sharma | 29 October 2026

FTSE 100 Watch: Haleon PLC (LSE:HLN) Faces a Fresh Test as Investors Assess Consumer Health Prospects

• Haleon PLC remains a constituent of the FTSE 100 and is sensitive to changing expectations for consumer health.

Ankur Sharma | 29 October 2026

FTSE 100 Watch: GSK plc (LSE:GSK) Faces a Fresh Test as Investors Assess Biopharmaceuticals Prospects

• GSK plc remains a constituent of the FTSE 100 and is sensitive to changing expectations for biopharmaceuticals.

Ankur Sharma | 29 October 2026

PureTech Health plc (LSE:PRTC): Could Clinical Pipeline And Capital Allocation Reshape the AIM market Investment Case?

The most relevant recent area of investor attention is clinical pipeline and capital allocation; this does not establish an independently verified price catalyst on 29 October.

Ankur Sharma | 29 October 2026

RUA Life Sciences Plc (LSE:RUA): Could June Interim Results And Cardiovascular Device Strategy Reshape the AIM market Investment Case?

The most relevant recent area of investor attention is June interim results and cardiovascular device strategy; this does not establish an independently verified price catalyst on 29 October.

Ankur Sharma | 29 October 2026
Support

Hi! How can we help you today?

Loading…